Combination chemotherapy with vincristin, actinomycin D, cyclophosphamide and adriamycin in soft-part sarcoma
Mori, O.; Takagi, K.; Kitagawa, T.; Harada, M.; Ogawa, I.
Gan no Rinsho. Japan Journal of Cancer Clinics 32(9): 998-1004
1986
ISSN/ISBN: 0021-4949 PMID: 3747164 Document Number: 270209
Fifteen patients with soft-part sarcoma were treated with combination chemotherapy consisting of vincristin, actinomycin D, cyclophosphamide and adriamycin (VACA therapy). The cumulative five-year survival rate by the Kaplan-Meier method was about 73%. This VACA therapy was effective for malignant fibrous histiocytoma and synovial sarcoma as well as rhabdomyosarcoma. Side effects such as anemia, leucocytopenia, nausea and alopecia were observed, but could be managed. VACA therapy is considered to be useful as a combination chemotherapy for patients with soft-part sarcoma.